These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30798622)

  • 61. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
    Sidler MA; Leach ST; Day AS
    Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Usefulness of Testing for Fecal Calprotectin in Pediatric Gastroenterology Clinical Practice.
    Lężyk-Ciemniak E; Tworkiewicz M; Wilczyńska D; Szaflarska-Popławska A; Krogulska A
    Med Princ Pract; 2021; 30(4):311-319. PubMed ID: 33120396
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question.
    Monteiro S; Dias de Castro F; Leite S; Moreira MJ; Cotter J
    Scand J Gastroenterol; 2019 Jan; 54(1):49-54. PubMed ID: 30663515
    [TBL] [Abstract][Full Text] [Related]  

  • 64. How to use faecal calprotectin in management of paediatric inflammatory bowel disease.
    Saha A; Tighe MP; Batra A
    Arch Dis Child Educ Pract Ed; 2016 Jun; 101(3):124-8. PubMed ID: 26848103
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease.
    Guardiola J; Lobatón T; Cerrillo E; Ferreiro-Iglesias R; Gisbert JP; Domènech E; Chaparro M; Esteve M; Rodríguez-Moranta F;
    Gastroenterol Hepatol; 2018 Oct; 41(8):514-529. PubMed ID: 30293556
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunoanalytical characteristics of fecal calprotectin.
    Desbène C; Gaillard O; Kapel N
    Ann Biol Clin (Paris); 2016 Dec; 74(6):725-734. PubMed ID: 27848924
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Faecal calprotectin: a marker of inflammation throughout the intestinal tract.
    Summerton CB; Longlands MG; Wiener K; Shreeve DR
    Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):841-5. PubMed ID: 12172403
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study.
    Ye L; Chen BQ; Wang SD; Shi H; Yang Z; Wang FY
    Scand J Gastroenterol; 2017 Oct; 52(10):1113-1119. PubMed ID: 28675068
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
    Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
    Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
    Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
    Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Rapid fecal calprotectin correlates with clinical and endoscopic severity of inflammatory bowel diseases.
    Tursi A; Elisei W; Giorgetti G; Picchio M; Brandimarte G
    Scand J Gastroenterol; 2013 Nov; 48(11):1359-60. PubMed ID: 23971760
    [No Abstract]   [Full Text] [Related]  

  • 72. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.
    Sipponen T; Kolho KL
    Scand J Gastroenterol; 2015 Jan; 50(1):74-80. PubMed ID: 25523558
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
    Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Calprotectin in feces a well-documented marker of gastrointestinal inflammation. Indicates disease intensity--normalization of values predict mucosal healing].
    Lasson A
    Lakartidningen; 2010 Oct 27-Nov 2; 107(43):2645-9. PubMed ID: 21137533
    [No Abstract]   [Full Text] [Related]  

  • 75. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.
    Sipponen T; Savilahti E; Kärkkäinen P; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Oct; 14(10):1392-8. PubMed ID: 18484671
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
    Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
    World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Avoid Endoscopy in Children With Suspected Inflammatory Bowel Disease Who Have Normal Calprotectin Levels.
    Heida A; Holtman GA; Lisman-van Leeuwen Y; Berger MY; van Rheenen PF
    J Pediatr Gastroenterol Nutr; 2016 Jan; 62(1):47-9. PubMed ID: 26252922
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical Diagnostics of Fecal Calprotectin: a Comparative Study of Actim® Calprotectin and LIAISON® Calprotectin.
    Miettinen JA; Vuolteenaho O; Hedberg P
    Clin Lab; 2022 Jan; 68(1):. PubMed ID: 35023670
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease.
    Iborra M; Beltrán B; Nos P
    Gastrointest Endosc Clin N Am; 2016 Oct; 26(4):641-56. PubMed ID: 27633593
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
    Klingberg E; Strid H; Ståhl A; Deminger A; Carlsten H; Öhman L; Forsblad-d'Elia H
    Arthritis Res Ther; 2017 Feb; 19(1):21. PubMed ID: 28148281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.